Contribution of PET Imaging to Radiotherapy Planning and Monitoring in Glioma Patients - a Report of the PET/RANO Group

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2021 Feb 4

PMID 33538838

Citations 54

Authors

Norbert Galldiks

Maximilian Niyazi

Anca L Grosu

Martin Kocher

Karl-Josef Langen

Ian Law

Giuseppe Minniti

Michelle M Kim

Christina Tsien

Frederic Dhermain

Riccardo Soffietti

Minesh P Mehta

Michael Weller

Jorg-Christian Tonn

Affiliations

Soon will be listed here.

Abstract

The management of patients with glioma usually requires multimodality treatment including surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for radiotherapy planning and follow-up after radiotherapy completion. In order to maximize the radiation dose to the tumor and to minimize toxic effects on the surrounding brain parenchyma, reliable identification of tumor extent and target volume delineation is crucial. The use of positron emission tomography (PET) for radiotherapy planning and monitoring in gliomas has gained considerable interest over the last several years, but Class I data are not yet available. Furthermore, PET has been used after radiotherapy for response assessment and to distinguish tumor progression from pseudoprogression or radiation necrosis. Here, the Response Assessment in Neuro-Oncology (RANO) working group provides a summary of the literature and recommendations for the use of PET imaging for radiotherapy of patients with glioma based on published studies, constituting levels 1-3 evidence according to the Oxford Centre for Evidence-based Medicine.

Citing Articles

Comparison of F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma.

Everard A, Versnel D, Ruijters V, Tolboom N, Philippens M, Snijders T Clin Transl Radiat Oncol. 2025; 52:100931.

PMID: 40041678 PMC: 11879608. DOI: 10.1016/j.ctro.2025.100931.

Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.

Rafanan J, Ghani N, Kazemeini S, Nadeem-Tariq A, Shih R, Vida T Int J Mol Sci. 2025; 26(3).

PMID: 39940686 PMC: 11817476. DOI: 10.3390/ijms26030917.

Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.

Histomolecular Validation of [F]-FACBC in Gliomas Using Image-Localized Biopsies.

Vindstad B, Skjulsvik A, Pedersen L, Berntsen E, Solheim O, Ingebrigtsen T Cancers (Basel). 2024; 16(14).

PMID: 39061219 PMC: 11275162. DOI: 10.3390/cancers16142581.

Biomarker-driven molecular imaging probes in radiotherapy.

Li H, Gong Q, Luo K Theranostics. 2024; 14(10):4127-4146.

PMID: 38994026 PMC: 11234278. DOI: 10.7150/thno.97768.

References

Lohmann P, Stavrinou P, Lipke K, Bauer E, Ceccon G, Werner J . FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2018; 46(3):591-602. DOI: 10.1007/s00259-018-4188-8. View

Grosu A, Weber W, Franz M, Stark S, Piert M, Thamm R . Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(2):511-9. DOI: 10.1016/j.ijrobp.2005.01.056. View

Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View

Douglas J, Stelzer K, Mankoff D, Tralins K, Krohn K, Muzi M . [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2005; 64(3):886-91. DOI: 10.1016/j.ijrobp.2005.08.013. View

Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann N . Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020; 15(1):88. PMC: 7171749. DOI: 10.1186/s13014-020-01519-1. View

Suchorska B, Jansen N, Linn J, Kretzschmar H, Janssen H, Eigenbrod S . Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7):710-9. DOI: 10.1212/WNL.0000000000001262. View

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9(5):453-61. DOI: 10.1016/S1470-2045(08)70125-6. View

Hayes A, Jayamanne D, Hsiao E, Schembri G, Bailey D, Roach P . Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018; 8(4):230-238. DOI: 10.1016/j.prro.2018.01.006. View

Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I . Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer. 2016; 16(1):769. PMC: 5052714. DOI: 10.1186/s12885-016-2806-z. View

10.

Crinion J, Ashburner J, Leff A, Brett M, Price C, Friston K . Spatial normalization of lesioned brains: performance evaluation and impact on fMRI analyses. Neuroimage. 2007; 37(3):866-75. PMC: 3223520. DOI: 10.1016/j.neuroimage.2007.04.065. View

11.

Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

12.

Leimgruber A, Hickson K, Lee S, Gan H, Cher L, Sachinidis J . Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. Eur J Nucl Med Mol Imaging. 2020; 47(6):1476-1485. DOI: 10.1007/s00259-020-04706-0. View

13.

Levin V, Bidaut L, Hou P, Kumar A, Wefel J, Bekele B . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010; 79(5):1487-95. PMC: 2908725. DOI: 10.1016/j.ijrobp.2009.12.061. View

14.

Salber D, Stoffels G, Pauleit D, Oros-Peusquens A, Shah N, Klauth P . Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007; 48(12):2056-62. DOI: 10.2967/jnumed.107.046615. View

15.

Ruben J, Dally M, Bailey M, Smith R, McLean C, Fedele P . Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006; 65(2):499-508. DOI: 10.1016/j.ijrobp.2005.12.002. View

16.

Schon S, Cabello J, Liesche-Starnecker F, Molina-Romero M, Eichinger P, Metz M . Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging. 2020; 47(6):1468-1475. PMC: 7188730. DOI: 10.1007/s00259-019-04677-x. View

17.

Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N . 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg. 2018; 131(3):676-686. DOI: 10.3171/2018.4.JNS1859. View

18.

Wang Y, Rapalino O, Heidari P, Loeffler J, Shih H, Oh K . C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 102(4):1024-1028. PMC: 7336810. DOI: 10.1016/j.ijrobp.2018.06.011. View

19.

Lipkova J, Angelikopoulos P, Wu S, Alberts E, Wiestler B, Diehl C . Personalized Radiotherapy Design for Glioblastoma: Integrating Mathematical Tumor Models, Multimodal Scans, and Bayesian Inference. IEEE Trans Med Imaging. 2019; 38(8):1875-1884. PMC: 7170051. DOI: 10.1109/TMI.2019.2902044. View

20.

Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J . Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018; 103:32-37. DOI: 10.1016/j.ejrad.2018.04.003. View